anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: This study aimed to evaluate the effect of Cognitive functional therapy (CFT) on plantar pressure distribution symmetry in chronic non-specific low back pain (CNSLBP) patients.
METHOD: forty females with NSCLBP (age range 30-50 years) were recruited for clinical trials. They were randomly divided into experimental and control groups (Each group had 20 patients). The patients in the experimental group received CFT for 8 weeks. The primary outcome was psychological variables inclusive of pain, kinesiophobia and disability. The secondary outcome was plantar pressure distribution symmetry which assessment in standing condition. The Covariance statistical method was used for data analysis.
RESULTS: The results of covariance analysis for primary outcome showed a significant difference (p < 0.05) with a reduction of 52 % in pain (p = 0.001), 12 % in kinesiophobia (p = 0.001) and 41% in disability (p = 0.001). Also, the results of covariance analysis for secondary outcome showed a significant difference in plantar pressure distribution symmetry of inter-limbs foot (p = 0.007), forward and backward in the right foot (p = 0.002) and forward and backward in the left foot (p = 0.001).
CONCLUSION: CFT reduces of pain, kinesiophobia and disability. In addition significant difference in the plantar pressure distribution symmetry was observed, which it is argued the plantar pressure asymmetric can be influenced by psychological factors.
FIELD: medicine. ^ SUBSTANCE: pharmaceutical composition is intended for cancer treatment. As active ingredient composition contains suberoylanilide-hydroxamic acid (SAHA) or its pharmaceutically acceptable salt or hydrate. Invention also relates to method of obtaining crystalline active ingredient SAHA. ^ EFFECT: definite profile of SAHA particles distribution according to their size, which in its turn results in improved profile of solubility in vitro and optimal SAHA bioavailability. ^ 27 cl, 16 dwg, 22 tbl, 17 ex
The vinyasa yoga practice will be 60 minutes in duration and includes standing, seated, and supine postures in the following sequences in order: integration, sun salutations, crescent lunge series, balancing, standing, back bending, and restorative series. Participants will be instructed to follow the cues provided in the video and to take any necessary modifications to make each yoga pose more accessible. Vinyasa yoga intervention level 1 will be performed for week 1, level 2 will be performed for week 2, and level 3 will be performed for weeks 3 and 4 of the intervention.
Patients undergoing hip replacement often experience moderate to severe acute pain post-surgery. Normally such pain is controlled when patients receive repeated doses of opioid analgesics. However, opioid therapy is commonly associated with side effects such as nausea, vomiting, sedation, constipation, addiction, tolerance, and respiratory depression. CG5503, a newly synthesized drug also acts as a centrally acting pain reliever but has a dual mode of action. The aim of this study is to investigate the effectiveness (level of pain control) and safety (side effects) of 3 dose levels of CG5503, in an immediate release, (IR) formulation, compared with no drug (placebo) or one dose level of oxycodone (an opioid commonly used to treat post-surgical pain). This study is a randomized, double-blind (neither investigator nor patient will know which treatment was received), active- and placebo-controlled, parallel-group, multicenter study to evaluate the treatment of acute pain from hip replacement surgery. The study will include a blinded 72 hour in-patient phase immediately following hip replacement surgery, during which patients will be treated with either 50-, 75-, or 100-mg CG5503 base IR, a placebo, or 10-mg oxycodone, and pain relief will be periodically assessed. Following this phase, patients wishing to continue treatment with CG5503 IR may enter an outpatient voluntary nonrandomized, open-label extension phase for 9 days during which they will receive 50- or 100-mg CG5503 IR. Assessments of pain relief include the pain intensity numeric rating scale (PI), pain relief numeric rating scale (PAR) and patient global impression of change scale (PGIC). Safety evaluations include monitoring of adverse events, physical examinations, and clinical laboratory tests. Venous blood samples will be collected for the determination of serum concentrations of CG5503 and oxycodone. The null hypothesis for the study is that efficacy results for all CG5503 IR dosage groups are equal to placebo based on the mean sum of pain intensity difference at 48 hours. The alternative study hypothesis is that at least 1 dose strength of CG5503 will be different from placebo in controlling pain at 48 hours. CG5503 base IR 50, or 75, or 100 mg, or oxycodone 10 mg, or placebo, 1 capsule taken by mouth every 4 to 6 hours during the 72 hour postsurgery phase of the study (one extra dose is allowed, if needed for pain); and CG5503, 50 mg base capsules, 1 to 2 tablets taken by mouth every 4 to 6 hours for up to 9 days during the open label portion of the study. All doses of study treatment will be taken with approximately 120 mL of water with or with food.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention describes pharmaceutical and diagnostic composition, which contains antibody molecule which is able to specifically recognize -A4-peptide/A4, where antibody molecule is monoglycosylated or double-glycosylated antibody molecule. Composition can contain mixture of said antibodies. Monoglycosylated antibody molecule contains one glycosylated asparagin (Asn) residue in position 52 od amino acid sequences of variable region of heave chain (VH), given in description, and double-glycosylated antibody molecule contains asparagin (Asn) residue in the same position of said sequences of both binding sites of antibody. Composition can also contain less than 5% of molecules of antibodies, in which none of antigen-binding centres contains said glycosylated asparagin residue in VH. ^ EFFECT: antibody isoforms, described in the invention, can be applied with high degree of efficiency in, for instance, pharmaceutical interference into amyloidogenesis or process of amyloid plaques formation, in particular, Alzheimer's disease. ^ 12 cl, 56 dwg, 2 tbl, 17 ex
The recommended adult dose of fludarabine phosphate injection is 25 mg/m2 administered intravenously over a period of approximately 30 minutes daily for five consecutive days. Each 5-day course of treatment should commence every 28 days. Dosage may be decreased or delayed based on evidence of hematologic or nonhematologic toxicity. Physicians should consider delaying or discontinuing the drug if neurotoxicity occurs. 

A number of clinical settings may predispose to increased toxicity from Fludarabine Phosphate Injection. These include advanced age, renal impairment, and bone marrow impairment. Such patients should be monitored closely for excessive toxicity and the dose modified accordingly.

The optimal duration of treatment has not been clearly established. It is recommended that three additional cycles of Fludarabine Phosphate Injection be administered following the achievement of a maximal response and then the drug should be discontinued.
Sinomenine (SIN), a bioactive isoquinoline alkaloid extracted from the roots and stems of Sinomenium acutum, is efficacious against various chronic pain conditions. Inhibition of microglial activation at the spinal level contributes to the analgesic effects of SIN. Microglial activation in the spinal dorsal horn is key to sensitising neuropathic pain. Consequently, this study aimed to investigate whether the antinociceptive effects of SIN in neuropathic pain are induced through microglial inhibition and the underlying mechanisms. In this study, we observed that SIN alleviated chronic constriction injury (CCI)-induced pain hypersensitivity, spinal microglial activation and neuroinflammation. Consistently, SIN evoked the upregulation of transforming growth factor-beta1 (TGF-β1) and phosphorylated Smad3 in the L4-6 ipsilateral spinal dorsal horn of CCI mice. Intrathecal injection of TGF-β1 siRNA and an activin receptor-like receptor (ALK5) inhibitor reversed SIN's antinociceptive and antimicroglial effects on CCI mice. Moreover, targeting Smad3 in vitro with siRNA dampened the inhibitory effect of TGF-β1 on lipopolysaccharide-induced microglial activation. Finally, targeting Smad3 abrogated SIN-induced pain relief and microglial inhibition in CCI mice. These findings indicate that the TGF-β1/ALK5/Smad3 axis plays a key role in the antinociceptive effects of SIN on neuropathic pain, indicating its suppressive ability on microglia.
Frailty is increasingly seen within the aging population and is driven largely by musculoskeletal declines. Nearly 9 million Veterans are now 65 years of age or older with impairments in functional capacity, reduction in quality of life, and an increase in the use of health care services and associated costs. An estimated 45-50% of those over the age of 85 are frail, which could represent well over 1 million Veterans. Aging, which significantly contributes to frailty, is highly correlated with reduced levels of nicotinamide adenine dinucleotide (NAD+), an essential mediator in mitochondrial function. Restoration of cellular NAD+ levels is gaining support as a therapeutic strategy to maintain and even enhance functional capacity during aging. Nicotinamide riboside (NR) - an NAD+ precursor - enhances physical activity and mitochondrial health in mice. Furthermore, NR was recently shown to be safe in human clinical trials for boosting NAD+, yet the benefits for human physical performance and muscle physiology are unknown. Therefore, the goal of this project is to establish a double-blind randomized control trial to assess the impacts of NR on functional capacity, muscle function and structure, and mRNA signaling in healthy older adults. Towards this goal, this study will investigate healthy older individuals between the ages of 65 and 85 who will receive NR or a placebo for a period of 3 months. Participants will be tested for frailty, gait speed, and muscle strength at each time point. Additionally, muscle biopsies and serum will be collected to assess changes in muscle fiber histology, mitochondrial biomass and activity, and mRNA profiles. This project will provide greater insight into NR supplementation as a therapeutic strategy to stave off frailty and maintain resilience during aging.
The invention provides compositions and methods for the treatment of multiple cancers. More specifically, the invention provides a pharmaceutical composition comprising yeast cells and, optionally, a pharmaceutically acceptable carrier. Typically the yeast cells are Saccharomyces cemvisiae. The yeast cells can be live or killed. In a typical embodiment, the yeast cells are heat-killed. The yeast cells can be introduced intratumorally or intravenously to induce apoptotic death of cancer cells.
Patients first received an unenhanced MRM, followed by a gadobutrol-enhanced MRM. Gadobutrol was administered at the standard dose of 0.1 mmol/kg bw \[0.1 ml/kg bw\] as an intravenous injection (i.v.) injection at a rate of 2 ml/sec. UMRM and CMRM image sets were evaluated in a randomized fashion. After the evaluation of the UMRM or CMRM the respective XRM was added and evaluated together with the UMRM images.
This invention provides a combination of a DNA strand/fragment and isotope therapy that is applied to a cancerous tissue to selectively kill cancer cells with minimal negative effects on surrounding non-cancerous cells. Linear DNA fragments with labeled isotope are able to be absorbed by the tumor cells and bind the tumor cell's DNA through recombination, and then the isotope kills the tumor cells. Illustratively, a gene or a DNA fragment is employed as a carrier to deliver the P-32 which can kill cancer cells through radioactive emission. The illustrative embodiment produces the compound/agent containing a DNA fragment and P-32 through use of conventional P-32 labeling techniques such as those employed in molecular biology experiments (for example experiments used to test gene expression and gene amplification potency). The same P-32 labeled DNA can be employed directly for cancer treatment through a novel medical treatment method. Appropriate doses are provided to patients as part of a medical treatment method.
The pathogenicity of many bacteria, including Bacillus cereus and Staphylococcus aureus, depends on pore-forming toxins (PFTs), which cause the lysis of host cells by forming pores in the membranes of eukaryotic cells. Bioinformatic analysis revealed a region homologous to the Lys171-Gly250 sequence in hemolysin II (HlyII) from B. cereus in over 600 PFTs, which we designated as a "homologous peptide". Three β-barrel PFTs were used for a detailed comparative analysis. Two of them-HlyII and cytotoxin K2 (CytK2)-are synthesized in Bacillus cereus sensu lato; the third, S. aureus α-toxin (Hla), is the most investigated representative of the family. Protein modeling showed certain amino acids of the homologous peptide to be located on the surface of the monomeric forms of these β-barrel PFTs. We obtained monoclonal antibodies against both a cloned homologous peptide and a 14-membered synthetic peptide, DSFNTFYGNQLFMK, as part of the homologous peptide. The HlyII, CytK2, and Hla regions recognized by the obtained antibodies, as well as an antibody capable of suppressing the hemolytic activity of CytK2, were identified in the course of this work. Antibodies capable of recognizing PFTs of various origins can be useful tools for both identification and suppression of the cytolytic activity of PFTs.
Real-world studies permit inclusion of a more diverse patient population and provide more information on the effectiveness of treatments used in routine clinical practice. This prospective, multicenter, observational study investigated the effectiveness and safety of ixazomib plus lenalidomide and dexamethasone (IRd) in 295 patients with relapsed/refractory multiple myeloma (RRMM) in routine clinical practice in Japan. Patients had a median age of 74 years, 80.0% were aged ≥ 65 years, 42.0% had received ≥ 3 lines of prior treatment, and 28.5% were "frail" according to the International Myeloma Working Group frailty score. After a median follow-up of 25.0 months, median progression-free survival (PFS) was 15.3 (95% CI 12.4-19.5) months, while median overall survival was not reached. The overall response rate was 53.9%, and 31.5% of patients had a very good partial response or better. In the subgroup analysis, median PFS was better in patients with 1 versus 2 or ≥ 3 lines of prior treatment (29.0 vs 19.2 or 6.9 months) and paraprotein versus clinical relapse (16.0 vs 7.9 months), but median PFS was not notably affected by frailty score or age group. Dose adjustment was more frequent among patients aged > 75 years, especially early after IRd treatment initiation. Treatment-emergent adverse events (TEAEs) of any grade occurred in 84.4% of patients and 24.7% of patients discontinued treatment due to TEAEs; no new safety concerns were found. These findings suggest that oral IRd triplet regimen is an effective and tolerable treatment option for RRMM patients in real-world settings outside of clinical trials.ClinicalTrials.gov identifier: NCT03433001; Date of registration: 14 February 2018.
Hyperplasia of the coronoid process of the mandible is a rare condition defined as an abnormal and progressive elongation of the coronoid process (unilateral or bilateral). Jacob disease is the name given to a pseudo-joint formation between the coronoid process and the zygomatic bone. The main clinical finding is a progressive, painless difficulty in opening the mouth, due to contact of the coronoid process with the posterior surface of the zygomatic bone or the medial surface of the zygomatic arch. To restore the mouth opening in a stable manner, resection of the elongated coronoid process followed by physiotherapy is the only effective treatment. Surgery (coronoidetomy or coronoidectomy) can be performed through intraoral or extraoral access. Intraoral coronoidectomy is the best surgical choice for most of the cases. However, in some cases, the intraoral surgical field prevents an adequate visualization of the osteotomy line. The authors present 5 consecutive clinical cases of hyperplasia of the coronoid process treated with an endoscopically assisted coronoidectomy using ultrasound bone-cutting instruments.
The present invention relates to a traditional Chinese medicine for treating acute and chronic pharyngitis and an application thereof, which belongs to the technical field of medicine for treating acute and chronic pharyngitis. The traditional Chinese medicine is characterized in that the raw material of the traditional Chinese medicine comprises plum blossom. The traditional Chinese medicine can be prepared from the following raw materials according to proportion by weight: 0.1 to 5.0 portions of plum blossom, 0.1 to 5.0 portions of akebia fruit, 0.1 to 5.0 portions of silktree albizzia bark, 0.1 to 5.0 portions of melon peel and 0.1 to 5.0 portions of tangerine peel. The present invention also relates to the application of the traditional Chinese medicine in treating acute and chronic pharyngitis. The raw materials of the traditional Chinese medicine for treating acute and chronic pharyngitis are Chinese herbal medicine, so the traditional Chinese medicine has the advantages of low cost, convenient preparation and convenient administration. The Chinese herbal medicine has synergistic effect, so the traditional Chinese medicine can radically treat acute and chronic pharyngitis.
The invention relates to an immunoadsorber for specific removal of bacterial endotoxins from fluids or aqueous, crystalline and/or colloidal solutions, emulsions and body fluids (e.g. blood, plasma, lymph, cerebrospinal fluid) and/or fluids (e.g. serum, dialysate) obtained from body fluids. The endotoxins are bonded (in vitro, ex vivo or in situ) to avian endotoxin antibodies and eliminated from said fluid. A method for the production of the inventive immunoadsorber is also disclosed. The invention can be used in medicine, veterinary medicine, biomedicine, biomedical techniques, dentistry, pharmacy, biomedical research, pharmaceutical research, medical research, food production and, optionally, environmental protection.
A transdermal patch timer comprising an indicator configured to indicate whether a predetermined period of time has elapsed; and an attachment mechanism configured to couple the transdermal patch timer to a transdermal patch. A method of manufacturing a transdermal patch comprising applying a transdermal patch timer to a transdermal patch. A further method of using a transdermal patch comprising: adhering the transdermal patch to the user; activating the transdermal patch timer on the transdermal patch; and removing the transdermal patch from the skin of a patient in response to observing that the transdermal patch timer shows a predetermined period of time has elapsed. An indicator can be arranged on the transdermal patch timer to be isolated from an active agent reservoir of the transdermal patch. The indicator can be a visual indicator e.g. a dye configured to change appearance over time or after the predetermined time has elapsed. The transdermal patch timer can be a carbon dioxide indicator.
This study is aimed to be conducted in randomised controlled trial, comparing between intervention group and placebo group. We include women with primary dysmenorrhea who also have low vitamin D level in this trial. Our primary outcome is to compare visual analog pain scale between intervention and placebo group after treatment. After randomised and allocated, these women will be given vitamin D 50,000 IU or placebo capsules orally weekly for 8 consecutive weeks. We monitor pain score daily from the cycle before the drugs started until complete 8-week course of the regimen mentioned. Also vitamin D levels will be monitored twice, one before treatment and the other after treatment.
FIELD: technology of agglomeration of substances difficultly soluble and sensible to hydrolysis, particularly, pharmaceutical active substances, for instance, acetylsalicylic acid. SUBSTANCE: method includes passing of difficultly soluble substance powder together with at least one water-soluble binder under conditions of free fall through steam temperature at temperature between 85 and 105 C without compaction. In this case, residence time of powder in steam zone amounts from 0.5 to 10 s. Formed sinter cake is dried under conditions of free fall so that in points of contact between initial particles, small bridges of solid substance are formed from formed bridges of liquid binder. Then final drying is effected in fluidized bed. Method is realized in steam-jet agglomerator where freely falling product curtain from powder mixture to be agglomerated is subjected to treatment with steam by means of steam nozzles. Adjacent to agglomerator lower part is a drier with fluidized bed so that agglomerated particles fall directly into fluidized bed. In this case, the drier is separated from steam zone. EFFECT: production of easily dispersible granules. 12 cl, 4 dwg
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to stable anhydrous polar non-proton peptide compounds. These stable preparations comprise peptide in anhydrous polar non-proton solvent. They can be stored at elevated temperatures for prolonged time and they are used for prolonged delivery of medicinal agent. Invention provides application of the preparation in hormone-dependent diseases in prolonged storage of preparation. EFFECT: improved and valuable properties of preparation, improved method of treatment. 33 cl, 6 tbl
In light of the current industrial evolution, exposure to cadmium has become a significant public health concern. Cadmium accumulates in the renal tubular cells and causes nephrotoxicity largely through disruption of the redox homeostasis, induction of inflammation, and suppression of the histone deacetylase SIRT1 expression. The current work aimed at exploring the protective capability of bergenin, a naturally-occurring methyl gallic acid derivative, against the cadmium-evoked nephrotoxicity. Male Wistar rats were treated either with cadmium alone or with cadmium and bergenin for a 7-day experimental period followed by collection of kidney and blood specimens that were subjected to biochemical, molecular, and histological investigations. The results revealed the ability of bergenin to improve the renal functions in the cadmium-intoxicated rats as evidenced by increased glomerular filtration rate, and decreased serum creatinine and blood urea nitrogen. Equally important, bergenin reduced the renal tissue injury and enhanced its redox homeostasis as indicated by decreased protein expression of the kidney injury marker KIM-1, reduced lipid peroxidation, and improved antioxidant potential and histopathological picture of the renal tissues. Mechanistically, bergenin reduced the renal tissue cadmium content, markedly up-regulated protein expression of SIRT1 that regulates inflammation and the redox status of the renal tissues. Additionally, it improved the expression of the major antioxidant transcription factor Nrf2 and its responsive gene products heoxygenase-1 and NAD(P)H quinone dehydrogenase 1 in the cadmium-intoxicated rats. In the same context, bergenin down-regulated the acetylation and the nuclear translocation of the inflammatory transcription factor NF-κB and reduced levels of its responsive gene products TNF-α and IL-1β, as well as the activity of the inflammatory cell infiltration biomarker myeloperoxidase. Collectively, the current study underscores the ameliorating activity of bergenin against the cadmium-evoked nephrotoxicity and highlights modulation of SIRT1, Nrf2, and NF-κB signaling as potential underlining molecular mechanisms.